Sartorius Stedim Biotech Stock (OTC: SRTOY)

Latest news for Sartorius Stedim Biotech (OTC:SRTOY) Stock

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.

SARTORIUS ST BT UNSP/ADR by Sartorius Stedim Biotech

Sartorius Stedim Biotech SA

<p>The Zacks Electronics &ndash; Miscellaneous Products industry has been suffering from challenging macroeconomic conditions, high levels of inventories with distributors and steep interest rates. The global economic turmoil is expected to keep the semiconductor capex under check, which does not bode well for industry participants in the near term. However, players like <strong>KLA</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/klac#NASDAQ">KLAC</a>), <strong>Flex</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flex#NASDAQ">FLEX</a>) and <strong>Daktronics</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dakt#NASDAQ">DAKT</a>) are benefiting from higher spending on advanced technologies, including augmented reality&nbsp;and virtual reality. Continuing investments in data centers, high-performance computing and 5G end markets are the key catalysts. Fab (foundry) expansion in the United States, South Korea, Taiwan and China, as well as higher spending on memory equipment, is expected to drive growth in 2024 and beyond.</p>
<p><strong>Industry Description</strong></p>
<p>The Zacks Electronics &ndash; Miscellaneous Products industry includes a number of original equipment manufacturers of air-conditioning systems, green energy solutions, remote-control systems, GPS navigation, home automation systems, healthcare devices, industry/factory automation, robotics, semiconductor and optical applications, and energy management solutions. The industry is evolving on digital transformation and the growing demand for silicon across multiple markets. The increasing cost of manufacturing bodes well for equipment suppliers, while the growing demand for silicon is a positive for semiconductor companies. Apart from the United States, companies in this industry are based in Japan, Germany, the Netherlands and Switzerland. These companies either have manufacturing operations in China and South-East Asia or generate significant revenues from these regions.</p>
<p><strong>3 Trends Shaping the Future of the Industry</strong></p>
<p><em><strong>Solid Capital Spending Drives Prospects</strong></em>: Technology transitions are driving product complexities, which are raising the demand for solutions provided by industry participants. Increasing investment in expanding manufacturing capacity by semiconductor companies is a key catalyst in the long run (irrespective of the near-term hiccups due to the challenging macroeconomic conditions). Since semiconductor companies are the major customers of miscellaneous electronics product manufacturers, the trend bodes well for industry participants. In addition, rising spending on advanced nodes &mdash; 7 nm, 5 nm and 3 nm processes from logic and foundry customers &mdash; favors industry participants. Notably, logic and foundry spending is anticipated to be healthy this year.</p>
<p><em><strong>Emerging Markets of Wearables, AR &amp; VR Drive Growth</strong></em>: Industry participants are riding on strong demand for wearables and AR and VR-supported display systems in defense, industrial, consumer applications and healthcare end markets. The adoption of AR and VR is increasing due to the growing proliferation of the metaverse.</p>
<p><em><strong>Challenging Macroeconomic Condition is a Headwind</strong></em>: Industry participants are suffering from a challenging macroeconomic condition globally, with enterprises showing reluctance in committing to multi-year deals. Persistent inflation and unfavorable forex trends do not bode well for industry participants.</p>
<p><strong>Zacks Industry Rank </strong></p>
<p>The Zacks Electronics &ndash; Miscellaneous Products industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #184, which places it in the bottom 26% of more than 250 Zacks industries.</p>
<p>The group&#39;s Zacks Industry Rank, which is the average of the Zacks Rank of all member stocks, indicates dim near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.</p>
<p>The industry&#39;s positioning in the bottom 50% of the Zacks-ranked industries is a result of the negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are pessimistic about this group&#39;s earnings growth potential. Since Jul 31, 2023, earnings estimates for the industry for the current year have moved south by 25.5%.</p>
<p>Given the bearish prospects, there are only a few stocks worth watching in the industry. But before we present those stocks, let&#39;s take a look at the industry&#39;s recent stock-market performance and valuation picture.</p>
<p><strong>Industry Lags S&amp;P 500, Broader Sector</strong></p>
<p>The Zacks Electronics &ndash; Miscellaneous Products industry has underperformed the S&amp;P 500 and the broader Zacks Computer &amp; Technology sector in the past year.</p>
<p>The industry has returned 9.6% during this period compared with the S&amp;P 500 composite&#39;s growth of 19.3% and the broader sector&#39;s return of 27%.</p>
<h3>One-Year Price Performance<br />
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/elcmpioperf_20240726.jpg" style="height:357px; width:620px" /></h3>
<p><strong>Industry&#39;s Current Valuation</strong></p>
<p>On the basis of the forward 12-month P/E, which is a commonly used multiple for valuing Electronics-Miscellaneous products companies, we see that the industry is currently trading at 21.32X compared with the S&amp;P 500&#39;s 21.03X and the sector&#39;s forward-12-month P/E of 25.88X.</p>
<p>Over the last five years, the industry has traded as high as 22.16X and as low as 17.89X, with the median being 18.12X, as the charts below show.</p>
<h3>Forward 12-Month Price-to-Earnings (P/E) Ratio</h3>
<p><img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/elecval_20240726.jpg" style="height:229px; width:620px" /></p>
<p><img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/elecval2_20240726.jpg" style="height:225px; width:620px" /></p>
<p><strong>Stocks to Buy Right Now</strong></p>
<p><strong>Daktronics</strong>: This Brookings, SD-based digital LED display technology and audio systems provider benefits from strong order growth.</p>
<p>This Zacks Rank #1 (Strong Buy) company is riding on strong demand in Live Events and International business unit orders. Daktronics shares have gained 73.5% year to date.</p>
<p>The Zacks Consensus Estimate DAKT&#39;s fiscal 2025 earnings has increased 34.5% to $1.13 per share over the past 30 days.</p>
<h3>Price and Consensus: DAKT</h3>
<p><img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/dakt_20240726.jpg" style="height:359px; width:620px" /></p>
<p><strong>KLA</strong>: This Zacks Rank #2 (Buy) company is benefiting from the strong performance of the wafer inspection business, owing to rising demand for advanced wafer inspection applications in leading-edge technology development.</p>
<p>This San Jose, CA-based company is benefiting from growing investments across multiple nodes and rising capital intensity in Foundry &amp; Logic.</p>
<p>The Zacks Consensus Estimate for fiscal 2025 has increased by a couple of cents to $28.19 per share over the past 30 days. KLA shares have jumped 31.3% year to date.</p>
<h3>Price and Consensus: KLAC</h3>
<p><img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/klac_20240726.jpg" style="height:358px; width:620px" /></p>
<p><strong>Flex</strong>: This Zacks Rank #2 company is gaining momentum from strong demand for next-generation mobility, including EV onboard electronics and advanced computing platforms for the software-defined vehicle, which is powering the automotive unit. Health Solutions&#39; business is bolstered by top-tier digital health/ medical device demand. Solid traction in AI-driven cloud spending is a positive factor.</p>
<p>Flex shares have gained 1.6% in the year-to-date period. The consensus mark for FLEX&#39;s fiscal 2025 earnings has been unchanged at $2.36 per share over the past 30 days.</p>
<h3>Price and Consensus: FLEX<br />
<img alt="" src="https://staticx-tuner.zacks.com/images/zadmin_tuner_image/flex_20240726.jpg" style="height:358px; width:620px" /></h3>
<p><a href="https://www.zacks.com/commentary/2310123/3-electronics-stocks-to-buy-from-a-challenging-industry?cid=CS-BENZ-FT-industry_outlook-2310123">To read this article on Zacks.com click here.</a></p>


Earnings

News

Small Cap

Markets

Analyst Ratings

Tech

Trading Ideas

DAKT

FLEX

KLAC

3 Electronics Stocks to Buy From a Challenging Industry

<p>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the c<i>adisegliatin</i> clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. <i>Cadisegliatin </i>is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment.</p>


Biotech

General

VTVT

vTv Therapeutics Announces FDA Has Placed A Clinical Hold On The Cadisegliatin Clinical Program Which Includes The Ongoing CATT1 Phase 3 Trial In Type 1 Diabetes

SEEL

Seelos Therapeutics Announces Nasdaq Panel Grants The Request For An Additional Period, Will Remain Listed On Nasdaq, To Regain Compliance With Rule 5550(b)(2)

<p>NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will report topline data from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) on Monday, July 29, 2024.</p>


NAMS

NewAmsterdam Pharma Announces Topline Data From Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia On Monday, July 29, 2024

<p>Throughout the last three months, 10 analysts have evaluated Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $62.2, a high estimate of $75.00, and a low estimate of $45.00. Surpassing the previous average price target of $60.00, the current average has increased by 3.67%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024140_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Dave among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Announces</td>
<td>Buy</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jeff Cantwell</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$54.00</td>
<td>-</td>
</tr>
<tr>
<td>Hal Goetsch</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dave. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dave compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Dave's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dave's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DAVE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dave analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Dave</h2>
<p>Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.</p>
<h3>Dave: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Dave displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>24.95%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Dave's net margin excels beyond industry benchmarks, reaching <strong>46.51%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Dave's ROE excels beyond industry benchmarks, reaching <strong>31.95%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dave's ROA excels beyond industry benchmarks, reaching <strong>12.93%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.6</strong>, Dave adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DAVE

A Glimpse Into The Expert Outlook On Dave Through 10 Analysts

<p>In the latest quarter, 4 analysts provided ratings for Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Dover, presenting an average target of $205.0, a high estimate of $219.00, and a low estimate of $193.00. This upward trend is apparent, with the current average reflecting a 3.4% increase from the previous average price target of $198.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024126_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Dover by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$193.00</td>
<td>$192.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$219.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dover. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dover compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dover's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dover's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOV/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dover analyst ratings.</strong></a></p>
<h2>Get to Know Dover Better</h2>
<p>Dover is a diversified manufacturer and solutions provider delivering equipment and components, consumable supplies, aftermarket parts, software digital solutions, and support services. It operates through five segments: engineered systems, clean energy, and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.</p>
<h3>Key Indicators: Dover's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Dover displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>0.72%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Dover's net margin is impressive, surpassing industry averages. With a net margin of <strong>30.19%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dover's ROE excels beyond industry benchmarks, reaching <strong>12.32%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>5.42%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Dover's debt-to-equity ratio surpasses industry norms, standing at <strong>0.77</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Dover Stock

<p><strong>LuxUrban Hotels Inc. ("LuxUrban" or the "Company")</strong> <strong>(NASDAQ:</strong><a href="https://www.benzinga.com/stock/LUXH#NASDAQ"><strong>LUXH</strong></a><strong>)</strong>, which secures long-term operating rights for entire hotels through Master Lease Agreements (MLA) under which it manages the hotel and rents out, on a short-term basis, rooms to business and vacation travelers, today announced the launch of a proposed follow-on public offering of shares of its common stock. The Company also intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock sold in this offering.</p>


Offerings

LUXH

LuxUrban Hotels Launches Proposed Public Offering; No Size Or Amount Disclosed

Trading Halt: Halted at 4:01:47 p.m. ET - Trading Halt: Halt News Pending

<p>During the last three months, 15 analysts shared their evaluations of Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Universal Health Servs, revealing an average target of $197.27, a high estimate of $256.00, and a low estimate of $162.00. Marking an increase of 9.9%, the current average surpasses the previous average price target of $179.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024102_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Universal Health Servs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$220.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$256.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$198.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$162.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$236.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$186.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$198.00</td>
<td>-</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$189.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$183.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Universal Health Servs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Universal Health Servs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Universal Health Servs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Universal Health Servs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UHS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Universal Health Servs analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Universal Health Servs</h2>
<p>Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two key segments: Acute Care Hospital Services and Behavioral Health Services. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.</p>
<h3>Understanding the Numbers: Universal Health Servs's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Universal Health Servs displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.85%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Universal Health Servs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.81%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Universal Health Servs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>4.22%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Universal Health Servs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.87%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Universal Health Servs's debt-to-equity ratio is below the industry average at <strong>0.85</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 15 Analyst Recommendations For Universal Health Servs

<p>Kentucky&#8217;s expedited <a href="https://www.benzinga.com/markets/cannabis/24/06/39537843/applications-open-kentucky-set-to-roll-out-medical-cannabis-in-2025">licensing process for medical cannabis</a> has seen significant interest, but the number of formal applications remains low, <a href="https://www.cannabisbusinesstimes.com/news/kentucky-medical-marijuana-legalization-licenses-sales-regulations-timeline-when-start-where-buy/">reported</a> by Cannabis Business Times. The state&#8217;s licensing portal, opened on July 1, has registered 489 accounts, yet only 17 applications have been submitted for the 74 available licenses as of July 19. The Kentucky Cabinet for Health and Family Services (CHFS), which oversees the state&#8217;s cannabis program, is processing these applications.</p>
<h3 class="wp-block-heading">Slow Start For High Demand</h3>
<p>Despite the initial rush to register on the licensing portal, the number of formal applications has been underwhelming. Of the 17 submitted applications, 11 are for dispensary licenses, two for processor licenses, and four for cultivator licenses. The state allows applicants to submit multiple applications within a license type but prohibits vertically integrated operations from the program onset.</p>
<h3 class="wp-block-heading">Regulatory and Economic Challenges</h3>
<p>Applicants must demonstrate they have sufficient capital, ranging from $50,000 for Tier 1 cultivators to $500,000 for Tier 3 cultivators. This financial burden, along with nonrefundable application fees, may be contributing to the slow application rate. Some registrants could still be in the process of raising the necessary capital.</p>
<p>Governor <strong>Andy Beshear</strong> has been a vocal advocate for cannabis reform in <a href="https://www.benzinga.com/topic/kentucky#more-news">Kentucky</a>, having <a href="https://www.benzinga.com/markets/cannabis/22/11/29748349/another-state-legalizes-mmj-possession-but-heres-what-kentucky-gov-beshears-exec-order-says">signed the medical cannabis legalization bill</a> in March 2023 and House Bill 829 in April 2024, which expedited the licensing timeline by six months. "This administration has been working hard to expedite the timeline for making medical cannabis available to Kentuckians with serious medical conditions," Beshear said in a recent press release.</p>
<h3 class="wp-block-heading">Criticism From Advocacy Groups</h3>
<p>Despite Beshear&#8217;s efforts, cannabis advocacy group NORML has criticized certain provisions in H.B. 829. These include criminal background checks for patients with previous felony convictions and mandatory evaluations of patients&#8217; medical histories before issuing medical cannabis recommendations. <strong>Lauren Bratcher</strong>, deputy director of Kentucky NORML, argued that these restrictive measures could hinder patient access to medical cannabis.</p>
<h3 class="wp-block-heading">Future Prospects And Industry Sentiment</h3>
<p>Kentuckians can begin applying for medical cannabis cards on January 1, 2025, though the timeline for dispensary sales remains unspecified. The state's regulators are partnering with medical boards to ensure that authorized physicians and nurses are available to issue medical cannabis certifications.</p>
<p>CHFS Secretary <strong>Eric Friedlander</strong> emphasized the administration&#8217;s commitment to safe and affordable access to medical cannabis. To support a fair and transparent licensing process, the state has provided resources, including YouTube webinars and a business licensing application guide, to assist applicants.</p>
<p>With over five weeks remaining in the application period, there is still time for interested parties to finalize their applications. The current interest suggests a promising future for Kentucky's medical cannabis industry though the slow start highlights the financial and regulatory hurdles that prospective operators face.</p>
<p><em>Cover image made with AI</em></p>


Cannabis

Regulations

Retail Sales

Kentucky's Medical Marijuana Licensing Process Off To A Slow Start Despite Lots Of Interest, Here's Why

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Align Tech</strong>.</p>
<p>Looking at options history for Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 37% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $229,860 and 3, calls, for a total amount of $341,228.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $280.0 for Align Tech over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Align Tech options trades today is 127.12 with a total volume of 540.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Align Tech's big money trades within a strike price range of $160.0 to $280.0 over the last 30 days.</p>
<h3>Align Tech Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024086_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$21.1</td>
<td>$19.3</td>
<td>$20.5</td>
<td>$240.00</td>
<td>$195.0K</td>
<td style="text-align: right;">177</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.5</td>
<td>$9.0</td>
<td>$9.75</td>
<td>$280.00</td>
<td>$117.0K</td>
<td style="text-align: right;">239</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$40.1</td>
<td>$37.2</td>
<td>$40.2</td>
<td>$260.00</td>
<td>$80.4K</td>
<td style="text-align: right;">172</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$5.2</td>
<td>$4.3</td>
<td>$5.2</td>
<td>$230.00</td>
<td>$51.4K</td>
<td style="text-align: right;">130</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>ALGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$23.2</td>
<td>$22.8</td>
<td>$22.8</td>
<td>$220.00</td>
<td>$38.7K</td>
<td style="text-align: right;">74</td>
<td style="text-align: right;">18</td>
</tr>
</tbody>
</table>
</p>
<h3>About Align Tech</h3>
<p>Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.</p>
<p>After a thorough review of the options trading surrounding Align Tech, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Align Tech</h3>
<ul>
<li>Trading volume stands at 950,728, with ALGN's price down by -2.36%, positioned at $220.72.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>What The Experts Say On Align Tech</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $326.0.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Align Tech with a target price of $310. </li>
<li>Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Align Tech, targeting a price of $325. </li>
<li>Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Align Tech with a target price of $330. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Align Tech, targeting a price of $315. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Align Tech with a target price of $350. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Align Tech with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

ALGN

Align Tech Unusual Options Activity

<p>HC Wainwright &amp; Co.  analyst Edward White   reiterates Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) with a Buy and maintains $7 price target.</p>


Price Target

Reiteration

PBYI

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Viking Therapeutics</strong>.</p>
<p>Looking at options history for Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) we detected 39 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 30% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $81,740 and 36, calls, for a total amount of $1,562,212.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $100.0 for Viking Therapeutics over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Viking Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Viking Therapeutics's significant trades, within a strike price range of $20.0 to $100.0, over the past month.</p>
<h3>Viking Therapeutics Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024081_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$3.0</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$100.00</td>
<td>$124.5K</td>
<td>2.4K</td>
<td style="text-align: right;">36</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$5.5</td>
<td>$4.4</td>
<td>$5.5</td>
<td>$80.00</td>
<td>$82.2K</td>
<td>1.7K</td>
<td style="text-align: right;">252</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$27.0</td>
<td>$24.5</td>
<td>$27.0</td>
<td>$40.00</td>
<td>$81.0K</td>
<td>34</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$100.00</td>
<td>$70.0K</td>
<td>2.6K</td>
<td style="text-align: right;">375</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$6.3</td>
<td>$6.0</td>
<td>$6.3</td>
<td>$65.00</td>
<td>$63.0K</td>
<td>1.5K</td>
<td style="text-align: right;">287</td>
</tr>
</tbody>
</table>
</p>
<h3>About Viking Therapeutics</h3>
<p>Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.</p>
<h3>Present Market Standing of Viking Therapeutics</h3>
<ul>
<li>With a volume of 8,312,421, the price of VKTX is up 2.5% at $66.3. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 89 days.</li>
</ul>
<h3>What Analysts Are Saying About Viking Therapeutics</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $104.33333333333333.</p>
<ul>
<li>In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $90. </li>
<li>Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Viking Therapeutics, targeting a price of $118. </li>
<li>Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Overweight with a new price target of $105.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


VKTX

Viking Therapeutics's Options: A Look at What the Big Money is Thinking

<p>In the latest quarter, 4 analysts provided ratings for Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Alignment Healthcare, presenting an average target of $9.25, a high estimate of $12.00, and a low estimate of $7.00. This current average reflects an increase of 32.14% from the previous average price target of $7.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024081_0_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Alignment Healthcare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alignment Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alignment Healthcare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Alignment Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Alignment Healthcare's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALHC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Alignment Healthcare analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Alignment Healthcare: A Closer Look</h2>
<p>Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.</p>
<h3>Alignment Healthcare: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Alignment Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>43.14%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Alignment Healthcare's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-7.4%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Alignment Healthcare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-32.32%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Alignment Healthcare's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-7.59%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Alignment Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.3</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ALHC

Critical Insights From Alignment Healthcare Analyst Ratings: What You Need To Know

<p>Deep-pocketed investors have adopted a bullish approach towards Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UPST usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Upstart Hldgs. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 43% bearish. Among these notable options, 3 are puts, totaling $119,326, and 13 are calls, amounting to $606,162.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $100.0 for Upstart Hldgs over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Upstart Hldgs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Upstart Hldgs's whale trades within a strike price range from $15.0 to $100.0 in the last 30 days. </p>
<h3>Upstart Hldgs Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024076_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$0.48</td>
<td>$0.42</td>
<td>$0.46</td>
<td>$29.00</td>
<td>$127.8K</td>
<td>2.3K</td>
<td style="text-align: right;">925</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$11.1</td>
<td>$9.9</td>
<td>$11.0</td>
<td>$25.00</td>
<td>$88.0K</td>
<td>541</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.25</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$70.00</td>
<td>$57.5K</td>
<td>1.2K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>UPST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/23/24</td>
<td>$3.5</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$27.00</td>
<td>$55.2K</td>
<td>55</td>
<td style="text-align: right;">223</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/09/24</td>
<td>$1.85</td>
<td>$1.73</td>
<td>$1.73</td>
<td>$30.00</td>
<td>$43.2K</td>
<td>1.0K</td>
<td style="text-align: right;">312</td>
</tr>
</tbody>
</table>
</p>
<h3>About Upstart Hldgs</h3>
<p>Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.</p>
<h3>Current Position of Upstart Hldgs</h3>
<ul>
<li>With a volume of 3,428,753, the price of UPST is up 4.89% at $27.02. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Upstart Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


UPST

Upstart Hldgs's Options: A Look at What the Big Money is Thinking

<p>Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) has outperformed the market over the past 15 years by 3.12% on an annualized basis producing an average annual return of 15.05%. Currently, Analog Devices has a market capitalization of $112.13 billion. </p>
<p><strong>Buying $1000 In ADI:</strong> If an investor had bought $1000 of ADI stock 15 years ago, it would be worth <strong>$8,256.12</strong> today based on a price of $225.97 for ADI at the time of writing.</p>
<h3>Analog Devices's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024073_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In Analog Devices 15 Years Ago Would Be Worth Today

<p>Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) has outperformed the market over the past 20 years by 1.81% on an annualized basis producing an average annual return of 10.12%. Currently, Ball has a market capitalization of $19.26 billion. </p>
<p><strong>Buying $1000 In BALL:</strong> If an investor had bought $1000 of BALL stock 20 years ago, it would be worth <strong>$6,935.82</strong> today based on a price of $62.05 for BALL at the time of writing.</p>
<h3>Ball's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024068_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BALL

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $6,900 Today

<p>Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor&#39;s dream. However, when you&#39;re an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.</p>
<p>Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company&#39;s earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.</p>
<p><strong>Equinix in Focus</strong></p>
<p>Headquartered in Redwood City, <strong>Equinix</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eqix#NASDAQ">EQIX</a>) is a Finance stock that has seen a price change of -4.48% so far this year. Currently paying a dividend of $4.26 per share, the company has a dividend yield of 2.21%. In comparison, the REIT and Equity Trust - Retail industry&#39;s yield is 4.23%, while the S&amp;P 500&#39;s yield is 1.58%.</p>
<p>Looking at dividend growth, the company&#39;s current annualized dividend of $17.04 is up 17.6% from last year. Over the last 5 years, Equinix has increased its dividend 5 times on a year-over-year basis for an average annual increase of 11.52%. Future dividend growth will depend on earnings growth as well as payout ratio, which is the proportion of a company&#39;s annual earnings per share that it pays out as a dividend. Right now, Equinix&#39;s payout ratio is 53%, which means it paid out 53% of its trailing 12-month EPS as dividend.</p>
<p>Earnings growth looks solid for EQIX for this fiscal year. The Zacks Consensus Estimate for 2024 is $34.98 per share, with earnings expected to increase 8.94% from the year ago period.</p>
<p><strong>Bottom Line</strong></p>
<p>Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. However, not all companies offer a quarterly payout.</p>
<p>Big, established firms that have more secure profits are often seen as the best dividend options, but it&#39;s fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, EQIX presents a compelling investment opportunity; it&#39;s not only an attractive dividend play, but the stock also boasts a strong Zacks Rank of #2 (Buy).</p>
<p><a href="https://www.zacks.com/stock/news/2310200/equinix-eqix-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-2310200">To read this article on Zacks.com click here.</a></p>


Dividends

EQIX

Equinix Could Be a Great Choice

<p>In the preceding three months, 10 analysts have released ratings for LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.4, with a high estimate of $67.00 and a low estimate of $50.00. Marking an increase of 19.33%, the current average surpasses the previous average price target of $48.10. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024055_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive LendingTree. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$67.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$56.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Ryan Tomasello</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jed Kelly</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LendingTree. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of LendingTree compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of LendingTree's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of LendingTree's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TREE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on LendingTree analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into LendingTree's Background</h2>
<p>LendingTree Inc is a United States-based company that is principally engaged in operating an online loan marketplace. The company provides online tools and resources that can help consumers find loans or other credit-based offerings They need, including mortgage loans, reverse mortgage, home equity, personal loans, auto loans, credit cards, student loans, small business loans, and other related offerings. The company offers consumers direct access to a broad range of lenders. They have three reportable segments which are Home, Consumer, and Insurance. The company generates match fees by matching consumers with lenders, and closing fees from lenders on loans when a transaction is closed. The company operates business solely in the United States.</p>
<h3>Key Indicators: LendingTree's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> LendingTree's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately <strong>-16.33%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> LendingTree's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>0.61%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> LendingTree's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.79%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> LendingTree's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.12%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> LendingTree's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>5.52</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TREE

What 10 Analyst Ratings Have To Say About LendingTree

<p>In the preceding three months, 4 analysts have released ratings for Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $31.5, a high estimate of $34.00, and a low estimate of $29.00. This current average reflects an increase of 12.5% from the previous average price target of $28.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722024031_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Five Star. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Five Star. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Five Star compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Five Star's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Five Star's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FSBC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Five Star analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Five Star</h2>
<p>Five Star Bancorp is a California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts.</p>
<h3>Five Star: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Five Star faced challenges, resulting in a decline of approximately <strong>-6.56%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Five Star's net margin is impressive, surpassing industry averages. With a net margin of <strong>37.59%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Five Star's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.68%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Five Star's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.3%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Five Star's debt-to-equity ratio is below the industry average at <strong>0.69</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Sartorius Stedim Biotech

News

Latest news for Sartorius Stedim Biotech (OTC:SRTOY) Stock